We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

146 hedge funds and large institutions have $79.3M invested in Nektar Therapeutics in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 27 increasing their positions, 49 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

509% more call options, than puts

Call options by funds: $329K | Put options by funds: $54K

1.23% less ownership

Funds ownership: 6.08% → 4.86% (-1.2%)

25% less funds holding

Funds holding: 194 → 146 (-48)

35% less capital invested

Capital invested by funds: $121M → $79.3M (-$41.8M)

45% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 49

67% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 72

Holders
146
Holders Change
-48
Holders Change %
-24.74%
% of All Funds
2.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
27
Reduced
49
Closed
72
Calls
$329K
Puts
$54K
Net Calls
+$275K
Net Calls Change
-$182K

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$11.5M
2
MAM
Monaco Asset Management
Monaco
+$6.58M
3
SCM
Sio Capital Management
New York
+$4.97M
4
Citadel Advisors
Citadel Advisors
Florida
+$4.86M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.16M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$22.7M
2
BlackRock
BlackRock
New York
-$19.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$5.44M
4
State Street
State Street
Massachusetts
-$4.45M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
WIM
126
WealthPlan Investment Management
Nebraska
$380 – – –
ACA
127
Atlas Capital Advisors
Wyoming
$345 – – –
PP
128
PFS Partners
New Jersey
$344 – – –
First Manhattan
129
First Manhattan
New York
$287 – – –
PNC Financial Services Group
130
PNC Financial Services Group
Pennsylvania
$222 +$32 +3 +13%
National Bank of Canada
131
National Bank of Canada
Quebec, Canada
$196 – – –
AWM
132
AllSquare Wealth Management
New York
$173 – – –
SIS
133
Strategic Investment Solutions
Illinois
$120 – – –
Northwestern Mutual Wealth Management
134
Northwestern Mutual Wealth Management
Wisconsin
$115 -$586 -55 -81%
SPIA
135
Steward Partners Investment Advisory
New York
$115 – – –
HI
136
Harbour Investments
Wisconsin
$89 – – –
NSIM
137
North Star Investment Management
Illinois
$72 – – –
FMII
138
Farmers & Merchants Investments Inc
Nebraska
$65 – – –
PGAM
139
Princeton Global Asset Management
New Jersey
$58 – – –
EARNEST Partners
140
EARNEST Partners
Georgia
$48 – – –
FGAM
141
Financial Gravity Asset Management
Texas
$46 – – –
GRP
142
Global Retirement Partners
California
$9 – – –
HNB
143
Huntington National Bank
Ohio
$1 – – –
PAMS
144
Pictet Asset Management (Switzerland)
Switzerland
– -$2.62M -248,045 Closed
Walleye Capital
145
Walleye Capital
New York
– -$895K -84,892 Closed
O
146
OrbiMed
New York
– -$735K -68,937 Closed
N
147
Nuveen
North Carolina
– -$357K -33,876 Closed
EP
148
Edgestream Partners
New Jersey
– -$335K -31,802 Closed
Legal & General Group
149
Legal & General Group
United Kingdom
– -$288K -27,355 Closed
Swiss National Bank
150
Swiss National Bank
Switzerland
– -$285K -27,047 Closed
4 5
6
7 8

NKTR Hedge Fund Activity: Q2 2023 in Review

146 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2023, worth a combined $79.3M — down 35% from $121M a quarter earlier.

Sellers outnumbered buyers: 72 funds closed out of NKTR and 24 opened new positions — a net loss of 48 holders — while 49 trimmed existing stakes and 27 added.

The largest buyer was Deep Track Capital, adding an estimated $11.5M. The largest seller was Invesco, cutting an estimated $22.7M.

  • 146 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2023, down from 194 in Q1 2023.
  • Funds reported $79.3M of Nektar Therapeutics stock for Q2 2023, down 35% quarter-over-quarter.
  • 24 funds opened new Nektar Therapeutics positions in Q2 2023 and 72 closed out, a net change of -48 holders.
  • The largest Nektar Therapeutics buyer in Q2 2023 was Deep Track Capital, an estimated $11.5M added.
  • The largest Nektar Therapeutics seller in Q2 2023 was Invesco, an estimated $22.7M sold.

Based on aggregated 13F filings for Q2 2023.